硫唑嘌呤在炎症性肠病（IBD）中抗TNF药物转换时的新作用。 - Suppr

Suppr

超能文献

New role for azathioprine in case of switching anti-TNFs in IBD.

作者信息

Papamichael Konstantinos, Cheifetz Adam S, Irving Peter M

机构信息

Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

出版信息

Gut. 2020 Jul;69(7):1165-1167. doi: 10.1136/gutjnl-2020-320677. Epub 2020 Feb 19.

DOI:10.1136/gutjnl-2020-320677

PMID:32075889

Abstract

摘要

相似文献

New role for azathioprine in case of switching anti-TNFs in IBD.硫唑嘌呤在炎症性肠病（IBD）中抗TNF药物转换时的新作用。

Gut. 2020 Jul;69(7):1165-1167. doi: 10.1136/gutjnl-2020-320677. Epub 2020 Feb 19.

Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病：英夫利昔单抗和硫唑嘌呤治疗成功

Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.

Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.英夫利昔单抗或硫唑嘌呤治疗对炎症性肠病患者的乙肝疫苗疗效有负面影响。

J Gastroenterol Hepatol. 2015 Nov;30(11):1591-5. doi: 10.1111/jgh.13001.

Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease.我们使用硫唑嘌呤是否为时过晚？炎症性肠病早期免疫调节的理由。

World J Gastroenterol. 2008 Sep 28;14(36):5512-8. doi: 10.3748/wjg.14.5512.

Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.溃疡性结肠炎和克罗恩病女性的分娩结局以及抗炎药物治疗的药物流行病学方面

Dan Med Bull. 2011 Dec;58(12):B4360.

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.炎症性肠病患者停用抗TNF药物后的病情演变：一项多中心长期随访研究

Am J Gastroenterol. 2017 Jan;112(1):120-131. doi: 10.1038/ajg.2016.569. Epub 2016 Dec 13.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明

Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.在炎症性肠病处于缓解期的患者中，由原研英夫利昔单抗转换为生物类似药 CT-P13 后的血清浓度（SECURE）：一项开放标签、多中心、四期非劣效性试验。

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.

Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.炎症性肠病中肿瘤坏死因子拮抗剂治疗效果不佳的指标。

Dig Liver Dis. 2017 Oct;49(10):1086-1091. doi: 10.1016/j.dld.2017.07.010. Epub 2017 Aug 1.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.

引用本文的文献

Assessing the therapeutic potential of rutin in alleviating symptoms of inflammatory bowel disease: a meta-analysis.评估芦丁缓解炎症性肠病症状的治疗潜力：一项荟萃分析。

Front Pharmacol. 2025 Apr 30;16:1539469. doi: 10.3389/fphar.2025.1539469. eCollection 2025.

New perspectives and prospects for the next generation of combination therapy in inflammatory bowel disease.炎症性肠病下一代联合治疗的新观点与前景

World J Gastroenterol. 2025 Feb 7;31(5):99462. doi: 10.3748/wjg.v31.i5.99462.

The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature.大麻素在炎症性肠病（IBD）治疗中的应用：文献综述

Cureus. 2023 Mar 14;15(3):e36148. doi: 10.7759/cureus.36148. eCollection 2023 Mar.

Preclinical evidence for quercetin against inflammatory bowel disease: a meta-analysis and systematic review.槲皮素治疗炎症性肠病的临床前证据：一项荟萃分析和系统评价。

Inflammopharmacology. 2022 Dec;30(6):2035-2050. doi: 10.1007/s10787-022-01079-8. Epub 2022 Oct 13.

Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn's Disease.粪便微生物群移植是一种对先前英夫利昔单抗治疗失败的克罗恩病患者有前景的转换疗法。

Front Pharmacol. 2021 May 17;12:658087. doi: 10.3389/fphar.2021.658087. eCollection 2021.

Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse.大麻素及其衍生物与炎症性肠病：超越滥用。

Int J Mol Sci. 2020 Apr 22;21(8):2940. doi: 10.3390/ijms21082940.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验